ABOUT VELICEPT

Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS).

PIPELINE

pipeline_v2

Solabegron has completed and demonstrated positive results in initial Phase II clinical studies for the treatment of overactive bladder (OAB) in women and irritable bowel syndrome (IBS).

NEWS + EVENTS

Velicept Therapeutics, Inc. Raises $21 Million in Series B Financing

Malvern, PA, December 1, 2015 (BUSINESS WIRE) – Velicept Therapeutics, Inc. announced today it has closed on the first tranche of a $21 million Series B financing…